185 related articles for article (PubMed ID: 22314616)
1. Older age, poor performance status and major comorbidities: how to treat high-risk patients with advanced nonsmall cell lung cancer.
Aggarwal C; Langer CJ
Curr Opin Oncol; 2012 Mar; 24(2):130-6. PubMed ID: 22314616
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy in elderly patients with advanced lung cancer. Part II: Treatment of non-small cell lung cancer (NSCLC).
Honecker F; Wedding U; Bokemeyer C;
Onkologie; 2004 Dec; 27(6):583-8. PubMed ID: 15591721
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.
Gridelli C; Aapro M; Ardizzoni A; Balducci L; De Marinis F; Kelly K; Le Chevalier T; Manegold C; Perrone F; Rosell R; Shepherd F; De Petris L; Di Maio M; Langer C
J Clin Oncol; 2005 May; 23(13):3125-37. PubMed ID: 15860872
[TBL] [Abstract][Full Text] [Related]
4. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
Hensing TA; Peterman AH; Schell MJ; Lee JH; Socinski MA
Cancer; 2003 Aug; 98(4):779-88. PubMed ID: 12910523
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic options for elderly patients with advanced non-small cell lung cancer.
Avery EJ; Kessinger A; Ganti AK
Cancer Treat Rev; 2009 Jun; 35(4):340-4. PubMed ID: 19155139
[TBL] [Abstract][Full Text] [Related]
6. Advanced non-small-cell lung cancer in the elderly.
Vamvakas L; Saloustros E; Karampeazis A; Georgoulias V
Clin Lung Cancer; 2009 May; 10(3):158-67. PubMed ID: 19443335
[TBL] [Abstract][Full Text] [Related]
7. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
Asmis TR; Ding K; Seymour L; Shepherd FA; Leighl NB; Winton TL; Whitehead M; Spaans JN; Graham BC; Goss GD;
J Clin Oncol; 2008 Jan; 26(1):54-9. PubMed ID: 18165640
[TBL] [Abstract][Full Text] [Related]
8. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
[TBL] [Abstract][Full Text] [Related]
9. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.
Hotta K; Fujiwara Y; Matsuo K; Suzuki T; Kiura K; Tabata M; Takigawa N; Ueoka H; Tanimoto M
Cancer; 2007 Mar; 109(5):939-48. PubMed ID: 17285602
[TBL] [Abstract][Full Text] [Related]
10. Lung cancer in the elderly.
Gridelli C; Langer C; Maione P; Rossi A; Schild SE
J Clin Oncol; 2007 May; 25(14):1898-907. PubMed ID: 17488989
[TBL] [Abstract][Full Text] [Related]
11. [Recent topics in chemotherapy for elderly patients with lung cancer].
Okamoto H; Watanabe K
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1097-104. PubMed ID: 10945002
[TBL] [Abstract][Full Text] [Related]
12. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
13. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
[TBL] [Abstract][Full Text] [Related]
14. Optimizing first-line treatment options for patients with advanced NSCLC.
Wakelee H; Belani CP
Oncologist; 2005; 10 Suppl 3():1-10. PubMed ID: 16368866
[TBL] [Abstract][Full Text] [Related]
15. The 800-lb gorilla we all ignore: treatment of NSCLC in elderly and PS 2 patients.
Devlin JG; Langer CJ
Clin Adv Hematol Oncol; 2007 Mar; 5(3):216-33. PubMed ID: 17519883
[TBL] [Abstract][Full Text] [Related]
16. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer.
Früh M; Rolland E; Pignon JP; Seymour L; Ding K; Tribodet H; Winton T; Le Chevalier T; Scagliotti GV; Douillard JY; Spiro S; Shepherd FA
J Clin Oncol; 2008 Jul; 26(21):3573-81. PubMed ID: 18640938
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.
Di Maio M; Chiodini P; Georgoulias V; Hatzidaki D; Takeda K; Wachters FM; Gebbia V; Smit EF; Morabito A; Gallo C; Perrone F; Gridelli C
J Clin Oncol; 2009 Apr; 27(11):1836-43. PubMed ID: 19273711
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the efficacy and safety of chemotherapy for patients with wet stage IIIB/IV non-small-cell lung cancer aged 80 years old or more.
Tamiya A; Naito T; Ono A; Ayabe E; Tsuya A; Nakamura Y; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
Lung Cancer; 2011 Feb; 71(2):173-7. PubMed ID: 20570388
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
Zhang YF; Chen ZW; Lu S
Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
[TBL] [Abstract][Full Text] [Related]
20. Management of advanced non-small-cell lung cancer in elderly populations.
Lilenbaum R
Clin Lung Cancer; 2003 Nov; 5(3):169-73. PubMed ID: 14667272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
